-
Mashup Score: 7
Hope S. Rugo, MD, FASCO, discusses updated safety findings from the ELEVATE trial of elacestrant-based combinations in ER+/HER2– metastatic breast cancer.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet
-
Mashup Score: 2
Hope S. Rugo, MD, FASCO, discusses how the combination of elacestrant and abemaciclib compares with other treatment options for patients with advanced breast cancer, whether estrogen receptor-positive or HER2-negative.
Source: www.targetedonc.comCategories: General Medicine News, Oncologists1Tweet-
WATCH: Hope S. Rugo, MD, FASCO, discusses how the combination of elacestrant and abemaciclib compares with other treatment options for patients with advanced breast cancer. @hoperugo @UCSFCancer @SABCSSanAntonio | #SABCS24 #bcsm #oncology https://t.co/h326Kf5pko
-
-
Mashup Score: 3San Antonio Breast Cancer Symposium - 13 day(s) ago
OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet-
We are LIVE onsite for the 2024 San Antonio Breast Cancer Symposium! We have a packed day of interviews with breast cancer experts, so stay tuned to see who we speak with today and the rest of this week! @SABCSSanAntonio #SABCS24 #bcsm #Oncology https://t.co/4sGPaN0m1O https://t.co/FcOBpTtjFs
-
-
Mashup Score: 3San Antonio Breast Cancer Symposium - 13 day(s) ago
OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet-
We are LIVE onsite for the 2024 San Antonio Breast Cancer Symposium! We have a packed day of interviews with breast cancer experts, so stay tuned to see who we speak with today and the rest of this week! @SABCSSanAntonio #SABCS24 #bcsm #Oncology https://t.co/4sGPaN0m1O https://t.co/FcOBpTtjFs
-
-
Mashup Score: 6
Albert Grinshpun, MD, MSc, discusses the utility of ctDNA as a predictive biomarker of endocrine therapy sensitivity in patients with HR+ breast cancer.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet-
WATCH: Albert Grinshpun, MD, MSc, discusses the utility of ctDNA as a predictive biomarker of endocrine therapy sensitivity in patients with HR+ breast cancer. @AlbertGrinshpun @shaarezedekmed @SABCSSanAntonio #SABCS24 #bcsm #oncology https://t.co/Yq0nVVjkeQ
-
-
Mashup Score: 11
Erica L. Mayer, MD, MPH, discusses findings with neoadjuvant niraparib plus dostarlimab in ER-positive, HER2-negative, BRCA/PALB2-mutated breast cancer.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet-
WATCH: Erica L. Mayer, MD, MPH, discusses findings with neoadjuvant niraparib plus dostarlimab in ER-positive, HER2-negative, BRCA/PALB2-mutated breast cancer. @elmayermd @DanaFarber @SABCSSanAntonio #SABCS24 #bcsm #oncology https://t.co/Iy5XbLT4yr
-
-
Mashup Score: 3San Antonio Breast Cancer Symposium - 13 day(s) ago
OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet-
We are LIVE onsite for the 2024 San Antonio Breast Cancer Symposium! We have a packed day of interviews with breast cancer experts, so stay tuned to see who we speak with today and the rest of this week! @SABCSSanAntonio #SABCS24 #bcsm #Oncology https://t.co/4sGPaN0m1O https://t.co/FcOBpTtjFs
-
-
Mashup Score: 4T-DXd Preserves QOL, Neurological Function in HER2+ Metastatic Breast Cancer Irrespective of Brain Metastases - 13 day(s) ago
T-DXd displayed favorable HRQOL and neurological function results in HER2+ metastatic breast cancer regardless of the presence of brain metastases.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet-
T-DXd Preserves QOL, Neurological Function in HER2+ Metastatic Breast Cancer Irrespective of Brain Metastases @SABCSSanAntonio #SABCS24 #bcsm #oncology https://t.co/tMFYHRjgY6
-
-
Mashup Score: 1Neoadjuvant Niraparib Plus Dostarlimab Generates pCRs in BRCA+ ER+/HER2– Breast Cancer - 13 day(s) ago
Treatment with preoperative niraparib plus dostarlimab generated responses among patients with BRCA-mutant, ER-positive, HER2-negative breast cancer
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet-
Neoadjuvant Niraparib Plus Dostarlimab Generates pCRs in BRCA+ ER+/HER2– Breast Cancer @SABCSSanAntonio #SABCS24 #bcsm #oncology https://t.co/iwFVnl7S87
-
-
Mashup Score: 3San Antonio Breast Cancer Symposium - 13 day(s) ago
OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet-
We are LIVE onsite for the 2024 San Antonio Breast Cancer Symposium! We have a packed day of interviews with breast cancer experts, so stay tuned to see who we speak with today and the rest of this week! @SABCSSanAntonio #SABCS24 #bcsm #Oncology https://t.co/4sGPaN0m1O https://t.co/FcOBpTtjFs
-
WATCH: Hope S. Rugo, MD, FASCO, discusses updated safety findings from the ELEVATE trial of elacestrant-based combinations in ER+/HER2– metastatic breast cancer. @hoperugo @UCSFCancer @SABCSSanAntonio #SABCS24 #bcsm #oncology https://t.co/YEO9Q5wljE